Biodesix reported a 42% year-over-year jump in Q1 2026 revenue and raised its full-year revenue guidance, citing increased diagnostic testing volume and improving economics. In the quarter ended March 31, revenue rose to $25.6 million from $18.0 million a year earlier, driven by higher test revenue. The company said diagnostic test volumes increased 29% year over year to 17,800, while average revenue per test rose largely due to expanded payer coverage and improvements in revenue cycle management. Biodesix also reported growth in development services revenue to $3.3 million. The update provides a near-term read on demand for its diagnostic offerings and suggests momentum that could help the company sustain growth expectations into 2026, particularly after the guidance raise to $108 million to $114 million for the year.